Allegro 3D
Develops DLP-based bioprinting technology for high-throughput manufacturing of biomedical devices, cell matrices, and precision human tissues for cell culture, drug screening, therapeutics, and regenerative medicine.
- CEO / Founder
- Wei Zhu
- Team Size
- 1-10
- Stage
- Acquired
- Total Funding
- $7.23M
- Latest Round
- Acquired
- Key Investors
- Small Business Innovation Research Awards, BICO
Technology & Products
Key Products
STEMAKER™ (automated DLP bioprinter for direct printing in 6-, 12-, and 24-well plates, compatible with CT/MRI/CAD)
Technological Advantage
Proprietary DLP bioprinting process achieves high-speed, high-precision tissue constructs, protected by 1 patent (application 10/7/2021) covering lithography, microfabrication, microtechnology, and molecular biology.
Differentiation
Value Proposition
Enables direct fabrication of 3D tissues in a rapid high-throughput manner, reducing lead times and enabling scalable biofabricated constructs for in vivo-like models and reduced animal testing dependency.
How They Differentiate
3x faster build speed than traditional extrusion bioprinters for high-throughput tissue constructs, with proprietary DLP technology enabling direct printing in multi-well plates for scalable applications.
Market & Competition
Target Customers
Researchers in tissue engineering, regenerative medicine, precision medicine, disease modeling, and drug discovery
Industry Verticals
Biotechnology; Pharmaceuticals; Medical Research
Competitors
TheWell Bioscience; Bioactive Regenerative Therapeutics; Obatala Sciences
Growth & Milestones
Growth Metrics
Acquired by BICO for an upfront enterprise value of $6 million USD with $5 million earnout contingent on performance, projected 2022 revenue of ~$1 million and positive EBITDA.
Major Milestones
2016: Founded in San Diego, CA; Pre-2022: Raised $1.23M; developed patented DLP bioprinting; May 6, 2022: Acquired by BICO for $6M upfront + $5M earnout (total $11M); Post-acquisition: Technology integrated into BICO/CELLINK portfolio